Viatris Looks To Call It A Day In US Januvia, Janumet Patent Saga
ANDA Sponsor And Originator Merck Look To Settle Hatch-Waxman Case
Viatris and Merck have disclosed plans to settle litigation currently pending before the US Court of Appeals for the Federal Circuit over the ANDA sponsor’s generic versions of its sitagliptin-containing medicines, Januvia (sitagliptin) and Janumet (sitagliptin/metformin).
You may also be interested in...
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.